Global Glycomics /Glycobiology Market Insights:
The global glycomics /glycobiology market is expected to generate revenue amounting to USD 1.05 billion in 2020, and is projected to reach to USD 2.38 billion by 2026, growing at a CAGR of 14.16% over the forecast period. Rising investments in research by various government bodies and development of novel drugs by pharmaceutical and biotechnology companies are some of the major factors driving the market growth for glycomics. Rising focus on glycomics and proteomics research studies is also propelling the market growth.
Increasing demand of personalized medicines for the treatment of different chronic diseases is also expected to boost the market growth during the forecast period. The major procedures for protein characterizations are evolving into advanced technologies, such as High Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Capillary Electrophoresis (CE) in chemical and biochemical research among others, which is driving the market growth for glycomics & glycobiology.
Growth in the proteomics market across various regions including North America, Europe, Asia Pacific, and Central & South America is further projected to propel the market growth of glycomics / glycobiology. However, the high cost of tools is likely to hamper the market growth during the forecast period.
Global Glycomics /Glycobiology Market Segmentation:
The global glycomics / glycobiology market is segmented on the basis of product into enzymes, instruments, kits, carbohydrates, and reagents & chemicals. The enzymes segment is further segmented into glycosidases & neuramidases, and glycosyltransferases & sialyltransferases, among others. The enzymes segment is expected to hold the largest market share in the global glycomics / glycobiology market during the forecast period. The consumable nature of enzymes and their wide applications in a variety of R&D and drug discovery procedures are the major factors driving the market for enzymes segment. Enzymes are used for different therapeutics such as direct antiviral, antibacterial, and anti-cancer activities among others. They are used for various treatments such as Tay-Sachs disease and Gaucher disease, and diabetes among others. The instruments segment is expected to grow significantly during the forecast period. Instruments are frequently used in drug discovery and diagnostic testing.
On the basis of application, the global glycomics / glycobiology market is segmented into drug discovery & development, and diseases & diagnostics. The drug discovery & development segment is expected to hold the largest market share and is also expected to grow at a high CAGR in the global glycomics /glycobioogy market during the forecast period. Increased government funding for research related to glycomics and proteomics along with growing R&D activities in pharma & biotechnology companies is driving the market growth. Growing number of drug discovery research activities in academic research institutes is also driving the market growth for glycomics/glycobiology.
On the basis of end users, the market is segmented into academic research institutes, pharmaceutical & biotechnology companies, and clinical laboratories. The academic and research institutes segment is expected to hold the largest market share in the global glycomics / glycobiology market during the forecast period. Collaborations between major organizations and research institutes are supporting the growth for the segment. Increasing adoption of glycan structure data analysis by research centers & institutes is also driving the market growth. Glycomics are widely preferred for training and educational purposes in academic institutes.
Global Glycomics /Glycobiology Market – Regional Analysis
On the basis of region, the market of glycomics / glycobiology is segmented into North America, Europe, Asia Pacific, Central & South America, and Middle East & Africa. The North America region is expected to hold the largest market share during the forecast period. The presence of leading players such as Agilent Technologies, Thermo Fisher Scientific, New England Biolabs, and Bruker Corporation are driving the market growth for glycomics & glycobiology in the region. Presence of well-established healthcare infrastructure and accessibility to advanced products is also driving the regional market. Government funding for R&D activities is another key factor boosting the glycobiology market growth in the region. Asia Pacific region is expected to grow at a high CAGR during the forecast period. Increasing number of pharmaceutical and biopharmaceutical industries have resulted in immense growth of glycomics in the region. Growing investments by Contract Research Organizations (CROs) for the development and production of drugs and biologics are expected to drive the market in the region during the forecast period.
Rise in demand for carpet materials in the infrastructure development sector is driving the market growth in the region. Growing demand from commercial applications such as hotels, hospitals, and public infrastructure is boosting the Glycomics / Glycobiology market as well.
According to 2018 BDO Biotech Briefing, the average R&D expenditure of the mid-sized biotech companies increased around 14% from 2016 to 2017
The Australian government invested approximately USD 10.4 billion for scientific research activities and innovations for the period 2017-2018. The Irish Government also invested around USD 5.6 billion spending program in 2015, to increasing the number of scientific research activities from 25,000 to 40,000.
In 2019, Merck invested around Euro 2.3 Billon in R&D. The company invested approximately Euro 1.66 Billion which is 75% of total R&D in healthcare division.
Thermo Fisher Scientific invested around USD 888 million in R&D in 2017. Agilent Technologies spent USD 339 million on R&D in 2017.
Avail customized purchase options to meet your exact research needs: